PMC:4548004 / 1898-2506 JSONTXT

{"project":"2_test","denotations":[{"id":"25912321-20440276-29848485","span":{"begin":202,"end":204},"obj":"20440276"},{"id":"25912321-16565240-29848486","span":{"begin":206,"end":208},"obj":"16565240"},{"id":"25912321-9306342-29848487","span":{"begin":346,"end":348},"obj":"9306342"},{"id":"25912321-14707435-29848488","span":{"begin":476,"end":477},"obj":"14707435"},{"id":"25912321-7611247-29848489","span":{"begin":479,"end":480},"obj":"7611247"},{"id":"25912321-16112122-29848490","span":{"begin":482,"end":484},"obj":"16112122"}],"text":"Therefore, we produced a new nephropathy model by provoking severe hyperlipidemia in SHR-cp/cp rats. Dyslipidemia in type 2 diabetes patients is a risk factor for the progression of kidney dysfunction [16, 23]. Dyslipidemia is also considered to be associated with an increased rate of progression of renal insufficiency in nondiabetic patients [17]. Several studies in animal models have shown that hypercholesterolemia accelerates the rate of progression of kidney disease [1, 5, 12]. Thus we intended to establish an animal model for the progressive loss of kidney function, exacerbated by hyperlipidemia."}

{"project":"MyTest","denotations":[{"id":"25912321-20440276-29848485","span":{"begin":202,"end":204},"obj":"20440276"},{"id":"25912321-16565240-29848486","span":{"begin":206,"end":208},"obj":"16565240"},{"id":"25912321-9306342-29848487","span":{"begin":346,"end":348},"obj":"9306342"},{"id":"25912321-14707435-29848488","span":{"begin":476,"end":477},"obj":"14707435"},{"id":"25912321-7611247-29848489","span":{"begin":479,"end":480},"obj":"7611247"},{"id":"25912321-16112122-29848490","span":{"begin":482,"end":484},"obj":"16112122"}],"namespaces":[{"prefix":"_base","uri":"https://www.uniprot.org/uniprot/testbase"},{"prefix":"UniProtKB","uri":"https://www.uniprot.org/uniprot/"},{"prefix":"uniprot","uri":"https://www.uniprot.org/uniprotkb/"}],"text":"Therefore, we produced a new nephropathy model by provoking severe hyperlipidemia in SHR-cp/cp rats. Dyslipidemia in type 2 diabetes patients is a risk factor for the progression of kidney dysfunction [16, 23]. Dyslipidemia is also considered to be associated with an increased rate of progression of renal insufficiency in nondiabetic patients [17]. Several studies in animal models have shown that hypercholesterolemia accelerates the rate of progression of kidney disease [1, 5, 12]. Thus we intended to establish an animal model for the progressive loss of kidney function, exacerbated by hyperlipidemia."}